Growth hormone prescribing and initial BMI SDS: Increased biochemical adverse effects and costs in obese children without additional gain in height
Daniel B. Hawcutt(University of Liverpool), Joanne Blair(Alder Hey Children's NHS Foundation Trust), Anne Povall(Alder Hey Children's NHS Foundation Trust), Paul Richardson(University of Liverpool), Matthew Peak(University of Liverpool), Victoria Price(Alder Hey Children's NHS Foundation Trust), Jennifer R Bellis(University of Liverpool), Paul Newland(Alder Hey Children's NHS Foundation Trust)
Cited by 13
Related Papers
Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine
|Journal of Hepatology|2000|205
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial
|The Lancet HIV|2020|177
Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19
|JAMA|2022|154
Severe hepatitis E infection during pregnancy
|Journal of Viral Hepatitis|1997|144